Below are the top 10 Pharmaceutical stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CBP) is on the list.
Marina Biotech, Inc. (NASDAQ:MRNA) has the 1st highest upside potential in this segment of the market. Its upside is 354.8%. Its consensus target price is $2.83 based on the average of all estimates.CytRx Corporation (NASDAQ:CYTR) has the 2nd highest upside potential in this segment of the market. Its upside is 258.9%. Its consensus target price is $3.00 based on the average of all estimates. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has the 3rd highest upside potential in this segment of the market. Its upside is 244.8%. Its consensus target price is $7.00 based on the average of all estimates.PharmAthene, Inc. (AMEX:PIP) has the 4th highest upside potential in this segment of the market. Its upside is 238.5%. Its consensus target price is $11.00 based on the average of all estimates. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has the 5th highest upside potential in this segment of the market. Its upside is 233.3%. Its consensus target price is $8.00 based on the average of all estimates.
China Botanic Pharmaceutical Inc (AMEX:CBP) has the 6th highest upside potential in this segment of the market. Its upside is 205.0%. Its consensus target price is $4.88 based on the average of all estimates. AVANIR Pharmaceuticals (NASDAQ:AVNR) has the 7th highest upside potential in this segment of the market. Its upside is 203.8%. Its consensus target price is $12.00 based on the average of all estimates. GenVec, Inc. (NASDAQ:GNVC) has the 8th highest upside potential in this segment of the market. Its upside is 201.2%. Its consensus target price is $1.13 based on the average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 9th highest upside potential in this segment of the market. Its upside is 194.1%. Its consensus target price is $2.00 based on the average of all estimates. XOMA Limited (NASDAQ:XOMA) has the 10th highest upside potential in this segment of the market. Its upside is 193.3%. Its consensus target price is $8.80 based on the average of all estimates.
No comments:
Post a Comment